In order to assist Stuart and Maxine Frankel in achieving their vision, Dean Marschall Runge, M.D., Ph.D., has assembled a world-renowned group of scientists and technology development professionals to serve as advisors to the Frankel Innovation Initiative program and provide their expertise and guidance to Frankel investigators.
In addition to reviewing project proposals, selecting awardees, and mentoring investigators, the Scientific Advisory Committee will leverage their vast experience to harness the creative ingenuity of the Frankel investigators and help direct the translation from cutting-edge innovation to life-saving medical practice.
We would like to extend our appreciation to the members of the Scientific Advisory Committee. The generous donation of their time, insight, and knowledge is key to the success of the Frankel Innovation Initiative.
Thomas F. Bumol, Ph,D., was the Senior Vice President of the Biotechnology and Immunology Research component at Lilly Research Laboratories, and the Site Head & President of Lilly’s Biotechnology Center of San Diego, which included the former Applied Molecular Evolution subsidiary of Lilly Research Laboratories and early clinical development for immunology assets from LRL (phase I and phase II) until his retirement on December 31st, 2017. Currently, Dr. Bumol is the Executive Vice President of the Allen Institute and Director of the Allen Institute for Immunology in Seattle, a position he assumed on March 1st 2018, for a new research institute focused on human immunology in both health and disease. This institute was launched on December 12th, 2018, funded by a 125 million dollar philanthropic gift from Paul G. Allen.
Elizabeth Bernstein, MBA, is an Analyst and Portfolio Manager on the public equity team at Vulcan Capital. Elizabeth focuses on investments in the healthcare sector. Most recently, Elizabeth was a Portfolio Manager at Invesco on the Mid-Cap Growth fund. In addition to her co-portfolio management role, Elizabeth was responsible for investing in the healthcare sector for the Mid-Cap Growth and Small-Cap Discovery funds. Prior to that, she was a Vice President at Allianz Global Investors Capital where she was an equity analyst covering the global healthcare and consumer sectors.
Elizabeth has a BA in History from the University of Pennsylvania and an MBA from the Ross School of Business at University of Michigan.
Eric Lefkofsky, JD, is the founder and CEO of Tempus, a leading provider of technology enabled precision medicine solutions. He is a founding partner of Lightbank, a venture fund investing in disruptive technologies. He is also the co-founder and Chairman of Groupon, a global e-commerce marketplace, and co-founder of Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics, a technology-enabled transportation and logistics outsourcing firm; InnerWorkings, a global provider of managed print and promotional solutions; and a founding investor of Uptake Technologies, a leading predictive analytics platform for the world’s largest industries.
Paul Meister, MBA, is co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services.
Meister recently served as President of MacAndrews & Forbes Incorporated. He previously served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting, and clinical research services to the pharmaceutical and biotech industries. Prior to that, he served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo.
During his tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively, as operations grew from two countries to 27 and sales expanded into 140 countries worldwide. Earlier in his career, Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.
Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of Aptiv PLC, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board, chair of the Provost Advisory Board, and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
Armen Shanafelt, Ph.D., is General Partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, Shanafelt held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Shanafelt currently serves as a director on the boards of Aeglea BioTherapeutics, Aileron Therapeutics, Protagonist Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Biomedical. He is a Kauffman Fellow (class of 2014).
Shanafelt received his Bachelor of Science degree in chemistry and physics from Pacific Lutheran University, and his Ph.D. in chemistry from the University of California, Berkeley.
William Slattery is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for ten years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.
David Walt, Ph.D., is the Hansjörg Wyss Professor of Biologically-Inspired Engineering at Harvard Medical School, Professor of Pathology at Brigham and Women’s Hospital, a Core Faculty Member of the Wyss Institute at Harvard University, and a Howard Hughes Medical Institute Professor. He is the scientific founder of Illumina Inc. and Quanterix Corp. and has co-founded several other life science start-ups. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors.
Teri Willey, MBA, is the Executive Director of IU Ventures and the Fund Manager of the IU Philanthropic Venture Fund. Teri’s career has been about starting and re-organizing university technology transfer programs and launching new early stage funds that invest in university science based ventures.
Teri served as Vice President of Cold Spring Harbor Laboratory leading a new program for industry engagement, new ventures, and intellectual property licensing; Vice President for Technology and Business Development for Mount Sinai School of Medicine; founding Chief Executive of Cambridge Enterprise, Ltd., the technology commercialization affiliate of the University of Cambridge in England which included the launch of the Discovery Fund; Co-founder and Managing Partner of ARCH Development Partners, a seed and early stage venture fund focused on university and corporate spin-outs; Business Development for Endocyte, Inc., University of Notre Dame Business School Adjunct Faculty; and Vice President of Start-ups at ARCH Development Corporation, a subsidiary of the University of Chicago, which commercialized technology from the University and Argonne National Laboratory. Her prior experience also includes non-executive board positions with a several early-stage companies, technology transfer leadership roles at Northwestern University and Purdue Research Foundation including the partnership to launch of Cook Biotech, founding membership on the Indiana 21st Century Fund Board and business development for International Minerals and Chemical.
Teri has been an advisor to policy makers, universities, and companies, is a past President of the Association of University Technology Managers (AUTM), a former Bye Fellow of Christ’s College Cambridge in England, and a Sagamore of the Wabash.
Tadataka “Tachi” Yamada, M.D., KBE, is a Venture Partner on the Life Science Team at Frazier Healthcare Partners. Tachi focuses on both creating companies, as well as providing strategic guidance to existing portfolio companies. Before joining Frazier, Tachi was Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the Board of Directors. In this role, Tachi was responsible for all of Takeda’s research & development activities, with a budget of nearly $4 billion.
Have questions about the Frankel Innovation Initiative? Contact Sara Risch, Biomedical Innovation Specialist, at email@example.com or 734-764-5598.